head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2024, vol. 30, issue1
Subject Area: Medicine
DOI: 10.5272/jimab.2024301.5339
Published online: 06 February 2024

Original article
J of IMAB. 2024 Jan-Mar;30(1):5339-5345
Nikolay Evtimov1, 2ORCID logoCorresponding Autoremail,
1) Department of Urology, Faculty of Medicine, Medical University Varna, Bulgaria.
2) MHAT ”St. Anna” Varna, Bulgaria.

Introduction: For more than 30 years, the idea of inhibiting growth factors has taken over the minds of different generations of scientists since the progression of the neoplastic process is determined by uncontrolled proliferation differentiation and apotosis and the metastasis of the neoangiogenesis process.
The aim: of this work is to show the density of immunohistochemical expression of NGF/TrkA and BDNF/TrkB A Trk B in tumor parienchyma and periprostatic adipose tissue. The study ability is to use it as a prognostic indicator for metastasis of prostate cancer.
Material and methods: During the period 2018-2022, 184 patients were diagnosed with radical prostateectomy on the occasion of localized prostate cancer with PSA < or > 20 nmoll/ml, Gleason< or >7, G< or >II. study of the density of expression besch determined by a semi-quantitative method and was established by counting epithelial cells associated with a monocronal antibody, calculated on 20 fields.
Results: The study showed expression of Trk receptors in epithelial cells in all tissue samples. NGF/TrkA has poor expression in adipose tissue in areas perirectally and ventrally in the pathoanatomical stage G1, and it becomes moderately positive as the process of undifferentiation progresses. The same tendency is observed in the expression of neurotrophin in prostate-epithelial cells.
Conclusions: The increased density of NGF, as well as the preoperative determination of the expression of  BDNF and TrK a,b receptors in the pathoantomic preparation, can be used as a negative prognostic indicator of the aggressiveness of the CaP tumor, as well as its possible metastasis.

Keywords: pathogenesis of prostate cancer, immunohistochemistry, growth factors, NGF, BDNF,

pdf - Download FULL TEXT /PDF 665 KB/
Please cite this article as: Evtimov N. Immunohistochemical expression of NGF/TrkA and BDNF/TrkB in tumor parienchyma and periprostatic adipose tissue, depending on the pathoanatomic stage of prostate cancer. J of IMAB. 2024 Jan-Mar;30(1):5339-5345. [Crossref - 10.5272/jimab.2024301.5339]

Corresponding AutorCorrespondence to: Assoc. prof. Nikolay Evtimov MD, PhD, DMSc,Department of Urology, Faculty Medicine, Medical University – Varna; 55, Marin Drinov str., Varna 9002, Bulgaria; E-mail: n_evtimov@abv.bg

1. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci. 2009;20(2):133-45. [PubMed]
2. Plo I, Bono F, Bezombes C, Alam A, Bruno A, Laurent G. Nerve growth factor-induced protein kinase C stimulation contributes to TrkA-dependent inhibition of p75 neurotrophin receptor sphingolipid signaling. J Neurosci Res. 2004 Aug 15;77(4):465-74.  [PubMed]
3. Salsabil L, Shahriar M, Islam SMA, Bhuiyan MA, Qusar MS, Islam MR. Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case-control study. J Int Med Res. 2023 Apr;51(4):3000605231166222.  [PubMed]
4. Dalal R, Djakiew D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol. 1997 Oct 31;134(1):15-22. [PubMed]
5. Krüffgen  A, Schneider  I, Wals  J. The  dark  side  of  NGF  family  neurotrophins  in  neoplasias. Brain Pathol. 2006 Oct;16(4):304-10.  [PubMed]
6. Montano  X,  Djamgoz  MB,  Epidermal  growth  factor,  neurotrophins  and  the  metastatic  cascade  in  prostate  cancer. FEBS Leff. 2004 Jul 30;571(1-3):1-8. [PubMed]
7. Molloy NH, Read DE, Gorman AM. Nerve growth factor in cancer cell death and survival. Cancers (Basel). 2011 Feb 1;3(1):510-30. [PubMed]
8. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005 Aug;6(8):603-14. [PubMed ]
9. Ceci FM, Ferraguti G, Petrella C, Greco A, Ralli M, Iannitelli A, et al. Nerve Growth Factor in Alcohol Use Disorders. Curr Neuropharmacol. 2021;19(1):45-60. [PubMed]
10. Hirose M, Kuroda Y, Murata E. NGF/TrkA Signaling as a Therapeutic Target for Pain. Pain Pract. 2016 Feb;16(2):175-82. [PubMed]
11. Wehrman T, He X, Raab B, Dukipatti A, Blau H, Garcia KC. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007 Jan 4;53(1):25-38. [PubMed]
12. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Bouhana KS, et al. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers. Bone. 2011 Feb;48(2):389-98. [PubMed]
13. Tajbakhsh A, Mokhtari-Zaer A, Rezaee M, Afzaljavan F, Rivandi M, Hassanian SM, et al. Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives. J Cell Biochem. 2017 Sep;118(9):2502-2515. [PubMed]
14. Ozono K, Ohishi Y, Onishi H, Nakamura K, Motoshita J, Kato M. et al. Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. Lab Invest. 2017 Nov;97(11):1332-1342. [PubMed]
15. Oyama Y, Nagao S, Na L, Yanai K, Umebayashi M, Nakamura K, et al.  TrkB/BDNF Signaling could be a new therapeutic target for pancreatic cancer. Anticancer Res. 2021 Aug;41(8):4047-4052. [PubMed
16. Tanaka K, Okugawa Y, Toiyama Y, Inoue Y, Saigusa S, Kawamura M,  et al.  Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer.    PLoS One. 2014 May 6;9(5):e96410. [PubMed]
17. Sochal M, Ditmer M, Gabryelska A, Białasiewicz P. The role of brain-derived neurotrophic factor in Immune-Related Diseases: a narrative review. J Clin Med. 2022Oct 12;11(20):6023. [PubMed]
18. Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G. et al.  ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020Feb;52(2):192-203. [PubMed]
19. Weeraratna AT,  Arnold JT, George DJ, DeMarzo A, Isaacs JT. Rational basis for Trk inhibition therapy for  prostate cancer. Prostate.2000Oct 1;45(2):140-8. [PubMed]
20. DiDonato M, Giovannelli P, Migliaccio A, Castoria G. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci.  2023 Mar 20;13(1):60. [PubMed]

Received: 13 July 2023
Published online: 06 February 2024

back to Online Journal